News

First-Line Nivolumab Plus Cabozantinib Yields Superior Efficacy vs Sunitinib for Renal Cell Carcinoma

09/06/2022

Final overall survival analysis from the phase 3 CheckMate 9ER trial demonstrate improved efficacy of nivolumab plus cabozantinib compared to sunitinib for the first-line treatment of patients with advanced renal cell carcinoma.

Final overall survival analysis...

09/06/2022

Oncology

News

Second-Line Cabozantinib Demonstrates Clinical Activity in Metastatic Renal Cell Carcinoma

08/31/2022

Allison Casey ;

Cabozantinib demonstrates meaningful clinical activity as a second-line treatment for patients with metastatic renal cell carcinoma, irrespective of prior exposure to VEGF inhibitors.

Cabozantinib demonstrates...

08/31/2022

Oncology

News

Prognostic Impact of Statin Use Among Patients With Renal Cell Carcinoma Receiving Nivolumab

08/22/2022

Allison Casey ;

Study findings reveal statin use improves the efficacy of nivolumab among patients with metastatic renal cell carcinoma.

Study findings reveal statin use...

08/22/2022

Oncology

News

Telaglenastat Plus Everolimus Improves PFS vs Placebo Plus Everolimus in Metastatic Renal Cell Carcinoma

07/29/2022

Allison Casey ;

Findings from a phase 2 trial show telaglenastat plus everolimus is well-tolerated and improves PFS vs placebo and everolimus among patients with metastatic renal cell carcinoma who had received prior treatment with TKIs and checkpoint...

Findings from a phase 2 trial...

07/29/2022

Oncology

News

Immune Checkpoint Inhibitors May Improve Survival Among Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

07/07/2022

Allison Casey ;

For patients with advanced non-clear cell renal cell carcinoma, immune checkpoint inhibitors in the first line appeared to be associated with improved overall survival when compared to vascular endothelial growth factor and mammalian target...

For patients with advanced...

07/07/2022

Oncology

News

Nivolumab Plus Ipilimumab Superior to Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma

06/13/2022

John Otrompke , BA, JD;

Nivolumab plus ipilimumab demonstrated durable clinical benefit over sunitinib for the first-line treatment of patients with advanced renal cell carcinoma after 5 years of follow-up, according to findings from the CheckMate 214 trial.

Nivolumab plus ipilimumab...

06/13/2022

Oncology

Conference Coverage

Perioperative Management of Clear Cell Renal Cell Carcinoma

03/30/2022

Janelle Bradley ;

In a presentation at the 2022 Great Debates and Updates in Genitourinary Oncology meeting, Bradley McGregor, MD, gave an update on the perioperative management of clear cell renal cell carcinoma.

In a presentation at the 2022...

03/30/2022

Oncology

News

Pembrolizumab Yields Significantly Longer DFS Than Placebo in Renal Cell Carcinoma

09/24/2021

Pembrolizumab was associated with significantly longer disease-free survival in comparison to placebo in a phase 3 trial developed to reduce the high risk of recurrence in patients with renal cell carcinoma after nephrectomy.

Pembrolizumab was associated...

09/24/2021

Oncology

News

FDA Approves Tivozanib for R/R Advanced RCC

03/11/2021

The FDA has approved tivozanib for the treatment of certain pre-treated patients with relapsed/refractory advanced RCC.

The FDA has approved tivozanib...

03/11/2021

Oncology

News

First-Line Pembrolizumab Demonstrates Antitumor Activity in ccRCC Patients

03/01/2021

Pembrolizumab monotherapy as a first-line treatment showed promising antitumor activity in treatment-naive ccRCC patients.

Pembrolizumab monotherapy as a...

03/01/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology